Precision nutrition pioneer L-Nutra will bring f

Evelyne Bischof on why credible training of doct

Paragon’s latest venture targets Alzheimer’s

Sava demonstrates its tiny, minimally invasive d

From a rare 14-month survival gain to a 65% lowe

A comprehensive competitive landscape analysis co

Research covering the sickle cell disease sector

A recent industry analysis finds that the global

Human Longevity, Inc.

Immortal Dragons, a Singapore‑based longevity i

Research indicates the global fallopian tube canc

Fresh backing from Michael J Fox Foundation and

Foodhak is using AI to make everyday eating more

New non-invasive wearable that uses AI and biose

Company aims to drug the ‘undruggable’ with

Declining stem cell release may reshape resilien

A global analysis forecasts the longevity market’s revenue to exceed US$740 billion in 2026 with sustained growth through to 2036. The research highlights a structural shift from consumer wellness offerings to healthcare‑oriented solutions supported by insurers, employers, health systems and pharmaceutical firms. This trend is creating demand for integrated platforms that support early risk detection, preventive care and ongoing clinical engagement. Technological advances in artificial intelligence, genomics and regenerative medicine are identified as key forces shaping the longevity market’s trajectory. AI‑enabled platforms are being used to analyse complex biological and longitudinal data to speed early‑stage discovery and prioritise therapeutic targets. Progress in gene‑editing and biomarker profiling is facilitating more targeted interventions for age‑related conditions under regulatory oversight. Regenerative medicine programmes are advancing cellular and tissue repair approaches aimed at improving resilience in major physiological systems. Leading companies in the field include AbbVie Inc., Alkahest, Inc., CELLINK, Elysium Health, Juvenescence Ltd., Insilico Medicine Life Biosciences, Inc., Rejuvenate Bio, Serina Therapeutics, Inc., Bristol-Myers Squibb Company, GSK plc, and others. Digital health tools, remote monitoring technologies and longevity clinic models are reinforcing market adoption by enabling proactive, data‑driven management of healthspan. Wearable devices that track physiological indicators and clinics combining diagnostics with AI‑guided…

Sana Biotechnology has appointed Brian Piper as E

Theriva Biologics has granted Rasayana Therapeuti

NeuroSense Therapeutics Ltd announced updated lon

EyePoint Pharmaceuticals has appointed Michael Ca

Zifo Technologies and Maze Therapeutics have ente

GenSight Biologics has expanded its Regulatory Af

Scribe Therapeutics has achieved a second success

UK Biobank study connects gray matter difference

Endurance Bio ready for Phase 2 trials of drug t

Buck Institute perspective argues for longitudin

Serotonin Anti-Aging Centers has awarded a five-l

Edelman’s ‘100-year life’ report suggests

The global oligonucleotide therapeutics market is

Harness Therapeutics has nominated HRN001 as a fi

Wellbeing International Foundation backs cell-fr

Sana’s early diabetes data suggest hypoimmune

Belgium’s long-time biotech backer is stepping

Weight-loss pills are reshaping the market, but

QuantalX Neuroscience leverages FDA De Novo clea

PD-AGE roadmap calls for older, standardized pre

Vesalic targets ‘toxic exosome’ identified i

Longevity biotech firm deepens UAE presence, lin

New $1.

New biotech ingredient mimics professional skin

HCW Biologics and WY Biotech announced the closin

AstraZeneca reported positive results from its Ph

Alnylam Pharmaceuticals reported significant fina

Serotonin Centers has opened a new location in Na

Spatial proteomics maps early molecular changes

Geromedicine Conference at NUS to focus on trans

One Medical’s latest offering analyzes members

Landmark CELL study uses live brain samples to m

Two longevity leaders team up to expand therapeu